A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

StatusRecruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 4 of 50 sites
    • Eligibility criteria expanded, about 2 words
  2. Site details revised at 1 of 50 sitesv15
  3. Study sites: 49 to 50v14
  4. Study sites: 50 to 49v13
  5. Trial sites reduced: 53 → 50 locationsv12
Show 2 earlier versionsHide 2 earlier versions
  1. Site details revised at 1 of 53 sitesv11
  2. Site details revised at 1 of 53 sitesv10
  1. Recruitment opened
    • Trial sites expanded: 50 → 53 locations
    • Start date changed from estimate of Mar 2026 to Mar 9, 2026
    v9
  2. Study sites: 51 to 50v8
  3. Study sites: 52 to 51v7
  4. Study sites: 53 to 52v6
  5. Study sites: 50 to 53v5
  6. Study sites: 51 to 50v4
  7. Study sites: 1 to 51v3
  8. Study site revisedv2
  9. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
Trial Details
NCT Number NCT07218341
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
Related terms Leukemia, Lymphocytic, Chronic, B-Cell
Enrollment 150 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov